logo

For the Inventor, By the Inventor

Steamboat Springs, CO, United States of America

Joanna Röder

LinkedIn
USPTO Granted Patents = 24 

 

Average Co-Inventor Count = 3.4

ph-index = 6

Forward Citations = 95(Granted Patents)


Company Filing History:

goldMedal24 out of 50 
 
Biodesix, Inc.
 patents
silverMedal2 out of 58 
 
Globeimmune, Inc.
 patents
bronzeMedal1 out of 5,445 
 
University of Texas System
 patents
where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...
Loading Chart...
24 patents (USPTO):Explore Patents
1. 12230398 - Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods (2025-02-18),
2. 12094587 - Apparatus and method for identification of primary immune resistance in cancer patients (2024-09-17),
3. 11894147 - Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings (2024-02-06),
4. 11710539 - Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy (2023-07-25),
5. 11621057 - Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy (2023-04-04),
6. 11594403 - Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sample (2023-02-28),
7. 11476003 - Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings (2022-10-18),
8. 11150238 - Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups (2021-10-19),
9. 10950348 - Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods (2021-03-16),
10. 10713590 - Bagged filtering method for selection and deselection of features for classification (2020-07-14),
11. 10593529 - Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies (2020-03-17),
12. 10489550 - Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample (2019-11-26),
13. 10217620 - Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry (2019-02-26),
14. 10037874 - Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry (2018-07-31),
15. 10007766 - Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods (2018-06-26),

Title: Joanna Röder: Innovator in Medical Predictive Analytics

Introduction

Joanna Röder is an accomplished inventor based in Steamboat Springs, Colorado, known for her significant contributions to medical predictive analytics. With a remarkable portfolio of 22 patents, her work focuses on developing advanced methodologies for predicting patient outcomes, particularly in critical healthcare scenarios such as COVID-19 and melanoma treatment.

Latest Patents

Among her latest patents is a groundbreaking method for predicting the risk of unfavorable outcomes for patients hospitalized with COVID-19. This innovation involves a sophisticated classifier that analyzes electronic health records, incorporating admission findings and laboratory data to stratify patients into high and low-risk groups. The hierarchical structure of the classifier, which combines decision trees with logistic models, enables more accurate predictions of patient outcomes, enhancing treatment decision-making.

Another notable patent addresses the prediction of melanoma patients' response to interleukin-2 therapy. By utilizing mass spectrometry data from blood samples, this method compares patient samples with a development set from other melanoma patients to predict treatment efficacy. The ability to guide therapy based on prior patient response data represents a significant advancement in personalized medicine.

Career Highlights

Joanna has honed her expertise through her work at notable companies, including Biodesix, Inc. and Globeimmune, Inc. Her roles in these organizations have allowed her to apply her innovative methodologies in practical settings, contributing to advancements in patient care and treatment strategies.

Collaborations

Throughout her career, Joanna has collaborated with esteemed colleagues, including Heinrich Röder and Julia Grigorieva. Their collective efforts in research and development have further propelled advancements in medical predictive analytics, fostering a collaborative environment for innovation.

Conclusion

Joanna Röder's extensive patent portfolio and her ongoing contributions to medical technology highlight her role as a pioneering inventor. Her innovative approaches in predicting patient outcomes not only reflect her expertise but also significantly impact clinical practice, paving the way for more effective healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…